DGX vs REPL · P/E 22, rev $9.87B vs $825.7M cap
Quest Diagnostics Incorporated (DGX) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported DGX revenue for 2024-12-31 was $9.87B. Net income was $921.0M. Revenue was up 6.7% from 2023-12-31 to 2024-12-31. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
REPL does not have a complete income-statement cache yet.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. REPL currently screens at market cap $825.7M.
Not investment advice. Open the DGX and REPL stock pages for the full models.
Not investment advice.